Monoclonal Antibody Against SARS-CoV-2

Monoclonal antibodies against the SARS-CoV-2 spike protein are being evaluated for prevention and treatment of COVID-19. Interim results of an ongoing, phase 2, industry-sponsored therapeutic trial (BLAZE-1) are now published. The investigators randomized 452 outpatients with mild or moderate COVID-19 to receive a single intravenous infusion of placebo or one of three doses of the investigational (not FDA-approved) monoclonal antibody LY-CoV555 (700, 2800, or 7000 mg).

Mean decrease in log viral load from baseline to day 11 (the primary endpoint) in the entire population was −3.81. Log viral load decreased −0.53 more, resulting in a 3.4-fold lower load, with 2800 mg of antibody than with placebo, a significant difference. Viral-load decline …